Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]

References

  1. ^ Wheate, Nial J. (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials" (PDF). Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/C0DT00292E. hdl:2123/14271. PMID 20593091.
  2. ^ Picoplatin Clinical Results, Poniard Pharmaceuticals
  3. ^ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
  4. ^ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009


Allikas: https://en.wikipedia.org/wiki/Picoplatin
No tags for this post.